In order to rescue NAD+ levels, we treated PBMCs purified from HD, CA, COV and COV/CA patients with a CD38 inhibitor (apigenin) and NAD+ precursors (leucin and nicotinamide). The gene discussed is CD38; the disease is Huntington disease.